Jeffrey Capello joins Flex Pharma's board
This article was originally published in Scrip
Executive Summary
Flex Pharma, a biotechnology company developing innovative treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, has named Jeffrey D Capello to its board of directors. Mr Capello is currently chief financial officer of Ortho-Clinical Diagnostics. He will also become chair of Flex's audit committee.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.